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Induction of VEGF and VEGF receptor gene expression by hypoxia:
Divergent regulation in vivo and in vitro. This study examined the
expression of EPO, VEGF and VEGF receptor gene under conditions of
reduced oxygen supply in primary cultures of rat hepatocytes, and
compared it with the expression of these genes in hypoxic rat livers in vivo.
To this end we exposed male Sprague-Dawley rats to hypoxia (10% and
8% 02), carbon monoxide (0.1% CO) or injected cobalt chloride (60
mg/kg CoCl2) subcutaneously. For the in vitro experiments we used
primary cultures of rat hepatocytes which were kept at high (20% 02) and
low (1% 02) oxygen tensions for three hours. The EPO mRNA was
up-regulated by hypoxia in vitro and in vivo about 10-fold. The VEGF
mRNA was up-regulated fivefold in the hepatocytes only, whereas the in
vivo mRNA levels remained unchanged. The mRNA levels of fit-I were
up-regulated threefold by 8% 02 in livers, dependent on the strength of
hypoxia (10% caused no changes in fit-i gene expression) and on the kind
of hypoxie stimulus (8% 02 was as effective as 0.1% CO and more effective
than cobalt). The mRNA levels of fik-1/KDR and fit-4 remained un-
changed in the liver. In vitro there were no changes in the mRNA levels of
fit-i, fit-4 and fik-1/KDR. Consequently, the in vivo regulation of VEGF,
which might be modulated by induction of fit-i receptor gene expression,
differs from the in vitro cell culture situation and might be different from
the EPO regulation in vivo.
Cells are able to sense low oxygen levels and to adapt to hypoxic
environments so that whole tissues are able to survive under
situations of insufficient oxygen delivery. For this adjustment to
low oxygen tensions several genes are up-regulated, like erythro-
poietin (EPO) [11, which controls erythropoesis, followed by a
higher oxygen carrying capacity of the blood or vascular endothe-
hal growth factor (VEGF), which controls angiogenesis in order
to improve oxygen delivery to hypoxic tissues [2, 31.Also, glyco-
lytic enzymes are induced which activate alternative metabolic
pathways working without oxygen supply [4, 5]. The transcription
of these genes is modulated by transcription factors like AP-1 or
Hif-1 [6, 7] and post-transcriptionally by mRNA stability [8]. Tn
cell culture experiments with cells, such as Hep3B and rat glioma
cells, similarities have been found between the oxygen sensing
mechanisms of EPO and VEGF [9]; both genes are up-regulated
by hypoxia, carbon monoxide, cobalt chloride and other divalent
cations [1, 2].
There is broad evidence that VEGF mRNA is up-regulated by
hypoxia in isolated cells [10—12], but its not yet clear if this
up-regulation is conserved in whole tissues [13, 14]. Recently, we
found that there is only a minor effect of hypoxia on the VEGF
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gene expression in vivo [14], suggesting that there may be differ-
ences in the in vivo regulation between the EPO and VEGF gene.
Recently evidence was provided that not only VEGF, but also its
receptors may be up-regulated by hypoxia in rat lungs [15], raising
the interesting question that the VEGF signal in tissues may be
modulated by up-regulation of both ligand and receptor. VEGF
receptors, like the receptors of other growth factors, such as
platelet-derived growth factor receptors (PDGFR), belong to the
family of tyrosine kinase receptors that show seven (or 5) immun-
globulin-like loops on the cell surface, a single transmembrane
segment, and an intracellular unit with a kinase domain insert
(KDR) [16]. So far, two VEGF receptors have been identified:
fit-i and fik-1/KDR [17—191. Two other receptors that are also
tyrosine kinases, fit-3 and fit-4, are rather homologous to fit-i and
might also serve as VEGF receptors [20—22]. This variety of
receptors should be able to fine tune the VEGF signal, which is
composed of different VEGF proteins resulting from alternative
exon splicing [23]. These VEGF isoforms may act as homo- or
heterodimers or heterodimers with placental growth factor
(PIGF) [24—26]. Recently, the ligand for fit-4 has been identified
as "VEGF-related protein (VRP)" [27].
Based on these previous findings, we were interested in the
question of whether there are differences between the regulation
of VEGF gene in the rat liver in comparison with rat hepatocytes
during hypoxia, if this regulation is dependent on the strength of
hypoxia or kind of hypoxic stimuli, and if the gene expressions of
VEGF receptor, fit-I fik-1/KDR and flt-4 are up-regulated, too.
Methods
Cell culture of hepatocytes
Rat hepatocytes were isolated as described in detail previously
[28]. After isolation the cells were seeded in tissue culture dishes
with gas permeable bottoms (Petriperm, Heraeus, Germany) and
incubated 40% 02 (5% C02, balance nitrogen) in humified
chambers at 37°C for four hours. Then nonattached cells were
removed by exchange of the culture medium and the cells were
incubated for a further three hours at 20% °2 (controls) or 1% 02
Cells were harvested and total RNA was isolated as described
previously [28].
Animal experiments
All animal experiments were conducted with the NIH Guide for
the Care and Use of Laboratory Animals and the German Law on
the Protection of Animals.
Male Sprague-Dawley rats (200 to 250 g) which had free access
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Fig. 1. Autoradiographie of an RNase protection
assay for fit-I, fit-4 and fik-I/KDR mRNA using
20 g of total liver RNA of a control rat—21 %
02 (lane A), of hypoxic rats kept at 10% 02
(lane B) or 8% 02 (lane C), of rats treated with
0.1% CO (lane D) and 60 mg/kg cobalt (lane E).
to food and water were used for the experiments. There were four
groups of rats.
A. Controls. These rats received no treatment.
B. Hypoxia treatment. The animals were placed in a gas tight box
and continuously gased with a mixture of 10% 02/90% N2 or 8%
02/92% N2 for six hours.
C. Carbon monoxide treatment. The animals were placed in a gas
tight box and continuously gased with room air plus 0.1% carbon
monoxide for six hours.
D. Cobalt treatment. These rats were subcutaneously injected
with cobalt chloride (60 mg/kg) and then sacrificed six hours later.
At the end of the experiments the animals were killed by
decapitation and blood was collected from the carotid arteries for
the determination of hematocrit. The livers were rapidly removed,
weighed, and rapidly frozen in liquid nitrogen. The organs were
stored at —80°C until isolation of total RNA.
Isolation of RNA
Total RNA was extracted from the frozen tissues according to
the protocol of as described previously [14]. The isolated RNA
was finally dissolved in DEPC (diethylpyrocarbonate) treated
water and stored at —80°C. The quality of obtained RNA was
routinely tested by the control of the 28S/18S rRNA band on an
1% ethidium bromid stained agarose gel.
RNase protection assay for EPO and VEGF
RNase protection assays for EPO [28] and VEGF [141 were
performed as described previously.
RNase protection assay fbr fit-I, fit-4 and fik-1/KDR
Fit-i, flt-4 and fik-1/KDR mRNA levels were measured by
RNase protection assay. To generate a cRNA probe able to detect
all three receptor tyrosine kinases in one cup, a 286 bp fragment
of fik-l/KDR, a 238 bp fragment of fit-i, and a 176 bp fragment of
flt-4, and mRNA were amplified by RT/PCR. For fit-i a combi-
nation of 5'Primer "fit-lA" (5'-CGGGATCCAAGGGACTCTA-
CACVFGTC-3') with 3'Primer "fit-1B" (5'-GGAATFCCCGAA-
TAGCGAGCAGA1TF-3') was choosen in the published sequence
[291, respectively, flt-4A (5'-CGGGATCCTGCTGTGGGATGAC-
CGCC-3') and fit-4B (5'-GGAATfCAGcFCATTGAJiTT-
TGG-3') [30], and for 11k-I, 5'Primer "fik-1A" (5'-CGGGATC-
CEATGCTGTATCfCGAGGGC-3') and 3'Primer "11k-B" (5'-
GGAATFCGT[TTGTCATCCCAGGGTAC-3') for fik-1 [31]. For
RT 1 xg of total lung RNA was reverse transcribed with 200 units
of M-MLV Transcriptase (Gibco/BRL) using standard protocols
and Oligo dt (Gibco/BRL) for priming reverse transcriptase
reaction. From the total volume of 20 d, 3 jxl of the eDNA were
used for the PCR. The reaction was performed in a final volume
of 20 1.d containing 2 1id 10 x concentrated buffer (supplied with
the enzyme), 2 p1 2.5 mM/liter dNTPs and one unit of Taq
Polymerase (Boehringer Mannheim). PCR conditions were 32
cycles with denaturation at 94°C (1 mm), annealing at 60°C (1
mm) and extension at 72°C (1 mm) for fit-i and fik-l cDNAs,
whereas fit-4 PCR annealing was done at 50°C and 32 cycles.
Purified fragments were cloned in the Polylinker site of pGEM 4Z
(Promega-Serva) for fik-i after HinclI (Pharmacia, Freiburg,
Germany) digest and psp 73 (Promega-Serva) for fit-i and flt-4
after BamHl/EcoRI (Pharmacia, Freiburg, Germany) digest.
Standard protocols for blunt-end cloning of fik-i and sticky-end
cloning of fit-i and fit-4 were used. After transformation into E.
coli DH 5a-positive clones were selected by size determination of
the plasniid insert after Smal/Hindlil (Pharmacia) for 11k-i and
BamHlIEcoRI (Pharmacia) digest for fit-i and fit-4. Sequencing
of the inserts done by SEQUISERVE (Dr. Metzger; Vaterstetten,
Germany) confirmed the identity of all cloned inserts with the
published sequences [29—31] and the orientation in the polylinker
site. All plasmids were linearized with Hindlil and yielded after
labeling with [c32P] GTP and Sp6 polymerase probes of the
expected size (345 bp for fik-i, 310 bp for fit-I and 250 bp for
fit-4). Figure 1 shows an autoradiography of the fit-I, flt-4 and
fik-1 RNase protection with 20 xg of total liver RNA. For all
assays 20 xg of total liver RNA were used.
Using the RNase protection assay for glycerine aldheyde phos-
phatedehydrogenase (GAPDH) GAPDH mRNA levels were
measured as described previously [32].
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comparison with the control group, but was significantly increased
(10-fold) by 8% 02 and to the same extent by CO inhalation. EPO
mRNA was also induced by cobalt administration about 2.5-fold.
For quality control we measured the housekeeping gene,
GAPDH, by the RNase protection assay for all RNAs used in this
study
VEGF mRNA expression in the rat liver
VEOF mRNA levels which were presented as the sum of
VEGF-188, VEGF-164 and VEGF-120, three amino acid iso-
forms of VEGF formed by alternative exon splicing from three
mRNAs [231, were also quantitated in normoxic and hypoxic rat
livers. The rank order of relative abundance in livers was VEGF-
188 > VEGF-164 > VEGF-120, which was not changed under
hypoxic conditions (not shown). No changes in VEGF mRNA
expression were found between the control group and the 10%
02, CO inhalation and cobalt injection groups (Fig. 2). The latter
two maneuvers were able to stimulate EPO mRNA in the same
livers about 10-fold and 2.5-fold, respectively. Only the 8% 02
group tended to increase VEGF levels from about 40 up to 50%,
on the borderline of significance. mRNA levels in all Figures are
expressed in counts per minute (cpm)/1 jxg total liver or hepato-
cyte RNA, allowing a comparison of the absolute abundance of
the quantitated mRNAs directly. The abundance of VEGF
mRNA in livers is markedly higher than that of EPO mRNA,
which is under normoxic conditions at the threshold of detectabil-
ity.
Fit-i, flt-4 and flk-i/KDR mRNA expression in the rat liver
Figures 1 and 3 show the hepatic mRNA levels of the tyrosine
kinase receptors fit-i, flt-4 and fik-I/KDR. The absolute abun-
dance for fit-I, fit-4 and fik-1/KDR was about 1:1:0.2. Inspiratory
hypoxia with 10% 02 had no effect on the mRNA levels of fit-i,
fit-4 and fik-1/KDR; 8% 02 increased fit-I mRNA threefold, but
had no influence on the flt-4 and flk-I/KDR gene expression. CO
was as effective as 8% 02 and stimulated fit-I gene expression
about threefold, whereas cobalt has a minor stimulating effect on
fit-i gene that was up-regulated twofold. The mRNA levels of flt-4
and fik-I/KDR were not changed by CO and cobalt (Figs. 1 and
3).
EPO mRNA expression in rat hepatocytes
Fig. 2. Abundance of EPO mRNA (A) and VEGF mRNA (B) in livers of
animals exposed to normoxia (21% 02), hypoxia (10% and 8% 07), carbon
monoxide or cobalt chloride. Values are expressed as radioactivity found in
the protected fragments (cpm) related tol tg total liver RNA. Data are
means SEM of 6 animals in each group.
Statistics
Levels of significance were estimated by ANOVA followed by
Student's unpaired t-test. P < 0.05 was considered significant.
Results
EPO mRNA expression in the rat liver
Figure 2 shows the EPO mRNA abundance in the rat livers
under normoxic conditions (21% 02) and the up-regulation of
EPO gene expression during hypoxia. EPO mRNA abundance in
the livers was not affected by 10% 02 inspiratory hypoxia in
After incubating cells three hours with 20% 02 (control group)
or 1% 02, EPO was not changed in the control preparation but
was substantially increased by hypoxia (Fig. 4).
VEGF mRNA expression in rat hepatocytes
The abundance of VEGF mRNAs and the rank order
(VEGF188 > VEGF-164> VEGF-120) did not change between
the rat liver and the primary culture of the hepatocytes, but was
markedly higher than the EPO mRNA in intact livers and
hepatocytes, as described above. VEGF mRNA levels significantly
dropped the incubation of the cells with 20% 02 for three hours.
After incubation at 1% 0, VEGF mRNA levels were increased
five- to sixfold in the hypoxie hepatocytes (Fig. 4).
Fit-i, flt-4 and flk-1IKDR mRNA expression in rat hepatocytes
As shown in Figure 4, fit-i, fit-4 and fik-i/KDR mRNA levels
were markedly lower than in intact livers, and we found only about
70
60
60
Q.-- 30
20
10
*
*
*
1
21%02 10%02
Hypoxic condition
8%02 0.1% CO
B C
Fig. 3. Abundance of.! It-I (0), JIt-4 (0) and
flk-l/KDI? () ,nRNA ii, I/nix of a,thnals
evposed to nonnoxia (21 '/ 0). Inpoxia (I oc?
and 8' 0,), carbon in, nIoLIuIe or cobalt
chloride. \'alues arc expressed as radioaclivity
found in the protected fragments (cpm) related
Lu I gg total liver RNA. Data are means sj-'
of 6 animals in each group.
0.6
0.5
o 0.4U-;
- 0.3U
0.2q) -LJ-
0.1
30
0
o 25
20
15
z
250
20
z
Sandner et al: Gene expression and hypoxia 451
20%02 1%02
Hypoxic condition
20% 02 1%02
Hypoxic condition
Fit-i Fit-4Fik-1 Fit-i Fit-4Fik-1
20% 02 1%02
Hypoxic condition
Fig. 4. Abundance of EPO (A), VEGF (B) and fit-I, fit-4, fik-l/KDR mRNA (C) in rat hepatocytes after three hours incubation at 20% °2 or1% 02. Vaiues
are expressed as radioactivity found in the protected fragments (cpm) related to I jig total liver RNA. Data are means SEM of three preparations in
each group.
1/10 of the abundance in hepatocytes after isolation and incuba-
tion at 20% 02. EPO and VEGF mRNA levels were unchanged
in intact livers and the primary cultures of the hepatocytes, as
mentioned before. After incubation at 1% instead of 20% 0 no
up-regulation of fit-I, fit-4 or fik-i/KDR mRNA could be mea-
sured, which was in sharp contrast to EPO and VEGF mRNA which
were substantially up-regulated in the cell culture by 1% °2 This
differed from the in vivo experiments where fit-I gene expression
could be up-regulated threefold during hypoxia (Fig. 3).
Discussion
The present study investigated and compared the expression of
EPO, VEGF and fit-i, fit-4 and fik-l/KDR gene expression in rat
livers and hepatocyte cell cultures under classical conditions of
hypoxia.
We observed a substantial up-regulation of EPO mRNA in vivo
and in vitro by all kind of hypoxic stimuli, which confirmed
previous findings [14, 28]. Cobalt was less effective in stimulating
EPO mRNA in total livers, which is also in keeping with our
previous findings [14].
Inspiratory hypoxia with 8% 02 was a rather modest stimulus
for VEGF gene transcription in the rat liver in comparison with
the 10-fold increase of EPO mRNA in the same livers (Fig. 2).
Thus our study provides further evidence that VEGF mRNA
expression in vivo does not follow the same pathway as EPO gene
expression [14].
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VEGF mRNA expression observed in vivo contrasted to the
up-regulation of VEGF mRNA in the hepatocyte cell cultures
where hypoxia caused a fivefold increase of VEGF mRNA (Fig.
4). This up-regulation of VEGF mRNA in cell culture experi-
ments by hypoxia fits with previous reports covering a variety of
cell types, such as hepatoma cell lines [9] or glioma cells [ii],
where this up-regulation during hypoxia has been described. One
could imagine that the relatively high basal expression of VEGF
mRNA in rat livers, which is about 350-fold higher than basal
EPO mRNA expression, reflects a constitutive expression that
appears to be oxygen independent and that can be stimulated to
a minor extent only by hypoxia. This raises the question if there
are other determinants which regulate VEGF gene expression in
a more substantially way.
In our study we also aimed to characterize the effect of acute
hypoxia on the gene expression of the receptor tyrosine kinases
fit-i, flt-4 and fik-i/KDR in the rat liver and in hepatocytes. Fit-i
bind VEGF and PIGf with high affinity, whereas flk-1 only binds
VEGF homodimers [24—26]. The ligand of flt-4 was recently
identified as a VEGF related protein [27]. Our results show that
fit-i and fit-4 were substantially expressed in the rat liver while the
expression of flk-i/KDR is relativly low (Figs. 1 and 3). This
distribution of fit-i and fik-1/KDR has already been reported [22,
29]. In the livers we observed a threefold induction of Fit-i
mRNA by 8% 02 and CO and a twofold induction by cobalt, but
no effect on the flk-iIKDR and fit-4 mRNA levels. Inspiratory
hypoxia by 10% 02 did not influence the mRNA levels of the
three tyrosine kinase receptors after six hours of exposure (Figs. 1
and 3). An up-regulation of fit-I and flk-1 has recently described
in lungs of rats exposed to an altitude of 16,000 feet [15].
Therefore, the regulation of fit-i gene paralleled that of EPO
gene expression (Fig. 2) which was up-regulated by 8% 02 and
CO, and to a minor extent by cobalt, suggesting that the regula-
tion of both genes would follow similar pathways under hypoxic
environments.
In the hepatocytes the basal expression of fit-i, flt-4 and
fik-1/KDR were markedly lower in comparison with the in vivo
mRNA levels (Figs. 3 and 4) and were not changed by incubation
at 1% 02. Two main explanations arise for this discrepancy. The
expression of fit-I, flt-4 and fik-1/KDR may depend on the age of
the rats used for the experiments. For the in vivo experiments we
used adult male rats (200 to 250 g) whereas for isolation of
hepatocytes young male rats (80 to 100 g) were used. For fit-i and
fik-i/KDR such a dependence of gene expression on the age of
rats has already been described [19, 3I. Finally, it cannot he
excluded that the main production site of the tyrosine kinase
receptors in livers is not localized in the hepatocytes. One can
speculate if Ito or Kupffer cells produce this mRNA to a much
more higher extent. For Ito cells such an expression for another
growth factor receptor, fibroblast growth factor receptor, bek, has
already been reported [34], and evidence has also been provided
that EPO is produced by Ito cells [35].
Taken together, our findings suggest that the expression of fit-I
gene, but not the expression of VEGF gene in livers, is regulated
in a way very similar to that of EPO gene. There were substantial
differences in the regulation of VEGF gene and fit-i, flt-4 and
fik-1/KDR genes in intact livers and in cell culture experiments,
assuming that the answer to hypoxia of VEGF and the VEGF
receptors follows different pathways in vivo and in vitro. Hypoxia
up-regulated fit-I mRNA selectively but not the other VEGF
receptor, flk-1/KDR mRNA, nor the related fit-4 mRNA.
Thereby it appears conceivable that hypoxia enhances the action
of VEGF not only via increased formation of the protein, but also
via induction of a particular VEGF receptor.
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